Gepotidacin mesylate is a Small Molecule owned by GSK, and is involved in 21 clinical trials, of which 17 were completed, 3 are ongoing, and 1 is planned.
Gepotidacin mesylate (GSK-2140944) is a triazaacenaphthylene bacterial type II topoisomerase II, IV and DNA gyrase inhibitor. They are molecular machines that regulate DNA supercoiling and separate interlocked chromosomes. Topoisomerases resolve the topological problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported. Topoisomerase is the second most abundant chromatin protein after histones and its biological roles include the decatenation of newly replicated DNA and the relaxation of polymerase-driven supercoils.
The revenue for Gepotidacin mesylate is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Gepotidacin mesylate NPV Report.
Gepotidacin mesylate is originated and owned by GSK.
Gepotidacin mesylate Overview
Gepotidacin mesylate (GSK-2140944) is under development for the treatment of uncomplicated urinary tract infection (acute cystitis) and Gram-negative bacterial infections like uncomplicated urogenital gonorrhea caused by neisseria gonorrhoeae and other bacterial infections. The drug candidate is administered orally as a capsule, tablet and intravenously as an infusion. It belongs to the bacterial topoisomerase type II, IV and DNA gyrase inhibitor (BTI) class of antibiotics. It is a new molecular entity. It was also under development for gram-positive acute bacterial skin and skin structure infections (ABSSSI), anthrax, plague and tularemia.
GSK Overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020.
The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.
Quick View – Gepotidacin mesylate
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies | |
Highest Development Stage |
|